This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence.
Journal of current glaucoma practice, 19(4), 223-228
Citation
Lang, Mary V; Vasu, Pranav; Dorairaj, Emily A; Bhartiya, Shibal; Dorairaj, Syril K. (2025). Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence.. Journal of current glaucoma practice, 19(4), 223-228. https://doi.org/10.5005/jp-journals-10078-1501